IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
Partner Insight Molecular Diagnostics (IMDX) reported progress on the FDA review of its GraftAssureDx test, which utilizes Bio-Rad's digital PCR instrument. Bio-Rad SVP Jonathan Seaton commented on the collaboration, emphasizing the suitability of Droplet Digital PCR for transplant monitoring and confidence in the commercialization path.
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.